COMMUNIQUÉS West-GlobeNewswire

Upstream Bio to Participate in Upcoming March Investor Conferences
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
25/02/2026
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer
25/02/2026
Pharmaceutical veteran with extensive late-stage development and commercial experience to lead Rivus as it advances its pipeline of oral medicines that leverage energy expenditure for the treatment of MASH, obesity, and [...]
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
25/02/2026
FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
Prime Medicine to Participate in Upcoming Investor Conferences
25/02/2026
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
25/02/2026
BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the [...]
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation
25/02/2026
CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or [...]
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
25/02/2026
Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys Data published in the American Journal of [...]
Helsinn Healthcare & InVirtuoLabs sign a Strategic Collaboration in AI-Driven Drug Discovery
25/02/2026
Partnership combines Helsinn proprietary compound library with InVirtuoLabs generative AI platform to accelerate discovery of novel therapeutics Lugano, Switzerland – February 25, 2026 – Helsinn Healthcare SA (Helsinn [...]
ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide
25/02/2026
The strategic partnership will also support the WHO resolution WHA78.13 with the aim to improve access to medical imaging and nuclear medicine February 25, 2026 – Wiesbaden, Germany. The International Centers for [...]
RYBREVANT®▼ (amivantamab) par voie sous-cutanée, approuvé par la Commission Européenne pour une administration toutes les trois ou quatre semaines chez les patients atteints d’un cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
25/02/2026
L’amivantamab sous-cutané (SC) réduit l’administration de plusieurs heures à quelques minutes, avec une efficacité et une sécurité comparables à celles de l’amivantamab intraveineux (IV) 1 ,2,3,4,5 L’amivantamab SC est [...]
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
25/02/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
Novonesis' Annual Report 2025
25/02/2026
Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: ”In 2025, we [...]
Ethris Part of Consortium to Receive up to EUR 148 Million European Commission Contract to Advance Novel Pandemic Influenza Vaccine
25/02/2026
Initial tender contract of EUR 13 million supports gated advancement into two subsequent competitive phases MUNICH, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethris GmbH , a clinical-stage biotechnology company pioneering next- [...]
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
25/02/2026
Please read the full announcement in PDF Attachment 2026_02_LTI
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
25/02/2026
Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary hypertension (PH) patients [...]
Novonesis delivered strong organic sales growth of 7% in 2025
25/02/2026
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester [...]
Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026
25/02/2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching respiratory support supplement options New York, NY, Feb. 24, 2026 (GLOBE [...]
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
25/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]

Pages